Misty Dawn Shields

ApeX Therapeutics (United States) — United States

Medicine · Health Sciences

9h-index688citations50works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(19), Lung Cancer Treatments and Mutations(16), Neuroendocrine Tumor Research Advances(7), Peptidase Inhibition and Analysis(7), Cancer Immunotherapy and Biomarkers(6)

Publications50 total

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
Molecular Cancer Therapeutics·2026
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer
Lung Cancer·2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026
Journal of the National Comprehensive Cancer Network·2026
Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series
Clinical Lung Cancer·2025
Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review
Clinical Lung Cancer·2025
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Cancer·2025
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity
Journal of Thoracic Oncology·2025· 5 cited
Increasing the Efficacy of ICB by Lurbinectedin Mediated Re-Activation of Tumor Microenvironment in SCLC
Journal of Thoracic Oncology·2025
Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma
Journal of Thoracic Oncology·2025
Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital.
Journal of Clinical Oncology·2025
Supervised home-based exercise in patients with advanced non-small cell lung cancer (NSCLC) on maintenance immune checkpoint inhibitors (ICI).
Journal of Clinical Oncology·2025
Outcomes with trilaciclib versus granulocyte colony stimulating factor regarding chemotherapy-associated adverse events, dose reductions, and subsequent therapies in small cell lung cancer.
Journal of Clinical Oncology·2025
Clinicogenomic features of non-small cell lung cancer patients with <i>BRAF</i> non-V600mutations.
Journal of Clinical Oncology·2025
Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer.
Journal of Clinical Oncology·2025
Does early versus late initiation of immunotherapy in extensive-stage small cell lung cancer affect survival outcomes?
Journal of Clinical Oncology·2025
Abstract 3037: Targeting pro-survival MYC oncogene expression in small cell lung cancer and large cell neuroendocrine carcinoma of the lung with a novel small molecule PIM2 inhibitor
Cancer Research·2025
PP01.14 Paired Sample Analyses of NSCLC After SCLC Transformation
Journal of Thoracic Oncology·2025
CLO25-059: Exploring Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Squamous Cell Carcinoma (LSCC) in North America
Journal of the National Comprehensive Cancer Network·2025
BPI25-018: Impact of Early Palliative Care on Outcomes in Small Cell Lung Cancer
Journal of the National Comprehensive Cancer Network·2025
CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)
Journal of the National Comprehensive Cancer Network·2025
page 1 of 3Next →

Frequent Co-authors

Mya Tran(13), Julian A. Marin‐Acevedo(12), Weston He(12), Ahmad Karkash(11), Nasser H. Hanna(7), Justin Wang Shi(7), Yan Han(6), Paresh Kumar(6), Theresa A. Boyle(5), Luc Girard(4), John D. Minna(4), Bruna Pellini(4), Utsav Sen(4), Elisa de Stanchina(4), Ling Zhang(4), Kenneth W. Minton(4), Balázs Halmos(4), Kenneth E. Huffman(3), Michael Peyton(3), David S. Shames(3)